HPV analysis
-73, probable/possible, Cancer
-11, CANCER
CVL were analyzed at the International Agency for Research on Cancer (IARC) in Lyon, France. There, a standardized methodology aimed at identifying all HPV strains has been established and used for worldwide HPV surveillance [The presence of HPV DNA was detected using a type-specific E7 PCR bead-based multiplex genotyping assay (E7-MPG, IARC, Lyon, France). The E7-MPG assay utilizes HPV type-specific primer pairs targeting the E7 region of 19 probable/possible high-risk (pHR) or high-risk (HR) HPV types (HPV-16, -18, -26, -31, -33, -35, -39, -45, -51, -52, -53, -56, -58, -59, -66, -68a and b, -70, -73, and -82) and two low-risk HPV types (HPV-6 and -11), plus primers for the amplification of a b-globin sequence [Following PCR amplification, 10 μl of each reaction mixture were analyzed by MPG using the Luminex technology as described previously (Luminex Corporation, Austin, Texas, USA) [Overall and type-specific HPV prevalence was estimated as the proportion of patients who tested HPV DNA positive for a given HPV DNA type.